Skip to main navigation

Skip to content

Careers
Contact Us
中文

Home
About
Research & Development
- Pipeline
- Technology Platforms
Therapies
Newsroom
Investors

Careers
Contact Us
中文

Press Releases

Overview
Press Releases
Events and Presentations
- Annual General Meeting
Corporate Governance
Stock Information
Financials
- SEC Filings
- Earnings Releases
Resources
- Email Alerts
- Contact IR

Year

Nov 12, 2024

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

Nov 07, 2024

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 05, 2024

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Nov 04, 2024

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Oct 24, 2024

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

Oct 03, 2024

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Sep 27, 2024

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Aug 20, 2024

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 09, 2024

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

Aug 08, 2024

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 27

GLOBAL HEADQUARTERS

2101 COTTONTAIL LANE

SOMERSET, NJ 08873, USA

+1-732-317-5050

Footer Links

ABOUT US
RESEARCH & DEVELOPMENT
THERAPIES
NEWSROOM
CAREERS
ETHICS & COMPLIANCE
COMPLIANCE HOTLINE
INVESTORS
COOKIE POLICY
PRIVACY POLICY
LEGAL NOTICE
CONTACT US
SITE MAP

© 2024 Legend Biotech. All rights reserved. dedication

You are about to leave Investors.LegendBiotech.com